TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NASONEX 24HR ALLERGY

MOMETASONE FUROATE
Approved 2022-03-17
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
3
Years on Market

Details

Status
Over-the-counter
First Approved
2022-03-17
Routes
NASAL
Dosage Forms
SPRAY, METERED

Companies

PERRIGO PHARMA INTL
Active Ingredient: MOMETASONE FUROATE

NASONEX 24HR ALLERGY Approval History

Loading approval history...

What NASONEX 24HR ALLERGY Treats

1 FDA approvals

Originally approved for its first indication in 2022 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NASONEX 24HR ALLERGY FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA215712 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.